DOI: https://doi.org/10.22141/2308-2097.52.3.2018.141846

Glycyrrizinic acid: pathophysiological aspects of fibrosis formation and effectiveness in treatment of liver diseases

Yu.М. Stepanov, V.B. Yagmur, А.V. Salenko

Abstract


The review article presents current data on the causes of the onset and development of liver fibrosis. This condition is due to excessive accumulation of the extracellular matrix, the producer of which is mainly hepatic stellate cells that, upon activation, can produce pathological collagen types I and III. The deposition of fibrillar tissue and collagen in the Disse space leads to the appearance of a basal membrane in the epithelium of the sinusoids that results in their capillarization. Portal hypertension is aggravated by endothelial dysfunction and pathological production of vasoconstrictors. Further progression of liver fibrosis is a risk factor for cirrhosis and even hepatocellular carcinoma. The data of studies on antifibrotic properties of glycyrrhizin, a herbal preparation, are given. Almost 40-year history of official study has proved its anti-inflammatory, antiviral, antifibrotic properties. The therapeutic effect of glycyrrhizin is due to the impact on immune cells, inhibition of hepatocyte apoptosis, and, on the contrary, to the acceleration of apoptosis of pathologically activated stellate cells. A selective influence on the transcription factors can explain the anticarcinogenic effect of the drug in case of chronic course of viral hepatitis.

Keywords


fibrosis; glycyrrhizin; apoptosis; hepatic stellate cells; collagen; carcinogenesis; review

References


Böttcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev. 2017 Nov 1;121:3-8. doi: 10.1016/j.addr.2017.05.016.

Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol. 1998 Sep;13 Suppl:S33-8.

Gressner AM1, Bachem MG. Molecular mechanisms of liver fibrogenesis – a homage to the role of activated fat-storing cells. Digestion. 1995;56(5):335-46. DOI: 10.1159/000201257.

García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012 Aug;57(2):458-61. doi: 10.1016/j.jhep.2012.03.007.

Kisseleva T, Brenner DA. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J Hepatol. 2012 Apr;56(4):965-72. doi: 10.1016/j.jhep.2011.09.021.

Li Y, Wang J, Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2324-9. doi: 10.1073/pnas.1214136110.

Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liverfibrosis. Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007.

Scholten D1, Weiskirchen R. Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury. Hepatology. 2011 Mar;53(3):1048-51. doi: 10.1002/hep.24191.

Chu AS, Diaz R, Hui JJ, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology. 2011 May;53(5):1685-95. doi: 10.1002/hep.24206.

Friedman SL. Mechanisms of Hepatic Fibrogenesis. Gastroenterology. 2008 May;134(6):1655-69. doi: 10.1053/j.gastro.2008.03.003.

Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008 Jan;88(1):125-72. doi: 10.1152/physrev.00013.2007.

Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000 Jan 28;275(4):2247-50.

Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol. 2008;43(6):419-28. doi: 10.1007/s00535-008-2180-y.

Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, awidely-used Chinese herb. Acta Pharm Sin B. 2015 Jul;5(4):310-5. doi: 10.1016/j.apsb.2015.05.005.

Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012 May;92(5):713-23. doi: 10.1038/labinvest.2012.45.

Thapaloya S, Wree A, Povero D, et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig Dis Sci. 2014 Jun;59(6):1197-206. doi: 10.1007/s10620-014-3167-6.

Liang B, Guo XL, Jin J, Ma YC, Feng ZQ. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol. 2015 May 7;21(17):5271-80. doi: 10.3748/wjg.v21.i17.5271.

Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002 Aug;2(8):594-604. doi: 10.1038/nrc864.

Guo XL, Liang B, Wang XW, et al. Glycyrrhizic acid attenuates CCl₄-induced hepatocyte apoptosis in rats via a p53-mediated pathway. World J Gastroenterol. 2013 Jun 28;19(24):3781-91. doi: 10.3748/wjg.v19.i24.3781.

Qu Y, Chen WH, Zong L, Xu MY, Lu LG. 18α-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells. Med Sci Monit. 2012 Jan;18(1):BR24-32.

Karsdal MA, Nielsen SH, Leeming DJ, et al. The good and the bad collagens of fibrosis–Their role in signaling and organ function. Adv Drug Deliv Rev. 2017 Nov 1;121:43-56. doi: 10.1016/j.addr.2017.07.014.

Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol. 2007 Nov;47(5):699-710. DOI: 10.1016/j.jhep.2007.05.015.

Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer. 2012 Jan 19;12:26. doi: 10.1186/1471-2407-12-26.

Castilla A, Prieto J, Fausto N. Transforming Growth Factors β1 and α in Chronic Liver Disease Effects of Interferon Alfa Therapy. N Engl J Med. 1991 Apr 4;324(14):933-40. doi: 10.1056/NEJM199104043241401.

Qu Y, Zong L, Xu M, Dong Y, Lu L. Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1292-301.

Tu CT, Li J, Wang FP, Li L, Wang JY, Jiang W. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. Int Immunopharmacol. 2012 Dec;14(4):410-21. doi: 10.1016/j.intimp.2012.08.013.

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008 Jan;214(2):199-210. doi: 10.1002/path.2277.

Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc. 2009;120:361-8.

Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011 Nov;4(6):391-417. doi: 10.1177/1756283X11413002.

Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10;388(10049):1081-1088. doi: 10.1016/S0140-6736(16)30579-7.

Preisser L, Miot C, Le Guillou-Guillemette H, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepa-titis C virusfibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology. 2014 Dec;60(6):1879-90. doi: 10.1002/hep.27328.

Presser LD, McRae S, Waris G. Activation of TGF-beta1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-beta1 in hepatic stellate cell activation and invasion. PLoS One. 2013;8(2):e56367. doi: 10.1371/journal.pone.0056367.

Benzoubir N, Lejamtel C, Battaglia S, et al. HCV core-mediated activation of latent TGF-beta via thrombospondin drives the crosstalk between hepatocytes and stromal environment. J Hepatol. 2013 Dec;59(6):1160-8. doi: 10.1016/j.jhep.2013.07.036.

Zan Y, Zhang Y, Tien P. Hepatitis B virus e antigen induces activation of rat hepatic stellate cells. Biochem Biophys Res Commun. 2013 Jun 7;435(3):391-6. doi: 10.1016/j.bbrc.2013.04.098.

Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress modulation in hepatitis C virus infected Cells. World J Hepatol. 2015 Dec 18;7(29):2880-9. doi: 10.4254/wjh.v7.i29.2880.

Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997 Apr 15;79(8):1494-500.

van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol. 1999 Nov;14(11):1093-9. doi: 10.1046/j.1440-1746.1999.02008.x.

Abe Y, Ueda T, Kato T, Kohli Y. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nihon Rinsho. 1994 Jul;52(7):1817-22.

Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants:results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737-42. doi: 10.1097/01.mcg.0000174023.7347.

Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015.

Matsui S, Matsumoto H, Sonoda Y, et al. Glycyrrhizin and related com-pounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004 Dec 15;4(13):1633-44. doi: 10.1016/j.intimp.2004.07.023.

Manns MP, Wedemeyer H, Singer A, et al. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat. 2012 Aug;19(8):537-46. doi: 10.1111/j.1365-2893.2011.01579.x.

Eisenburg J. Treatment of chronic hepatitis B. Part 2: Effect of glycyrrhizic acid on the course of illness. Fortschr Med. 1992 Jul 30;110(21):395-8. (in German).

Sato H, Goto W, Yamamura J, et al. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res.1996 May;30(2-3):171-7.

Li YW, Yang HZ, Ke QS, Chen W, Chen XJ. Effects of glycyrrhizin on the expression of hepatitis B virus and Toll like receptors 2,4 in HepG2.2.15 cells expressing low HBsAg. Zong Yao Cai 2008 Mar;31(3):403-7. (in Chinese).

Hung CH, Kee KM, Chen CH, et al. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol. 2017 Jun 29;8(6):e104. doi: 10.1038/ctg.2017.29.

Kang FB, Wang L, Sun DX. Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report. Medicine (Baltimore). 2017 Nov;96(44):e8518. doi: 10.1097/MD.0000000000008518.

Chen Q, Chen H, Wang W, et al. Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition. Eur J Pharm Sci. 2017 Aug 30;106:313-327. doi: 10.1016/j.ejps.2017.06.015.

Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:94-100. doi: 10.1159/000048283.

Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of gly-cyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand Scand J Gastroenterol. 2006 Sep;41(9):1087-94. doi: 10.1080/00365520600641365.

Hsiang CY, Lai IL, Chao DC, Ho TY. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci. 2002 Feb 22;70(14):1643-56.

Shiota G, Harada K, Ishida M, et al. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis. 1999 Jan;20(1):59-63. doi: 10.1093/carcin/20.1.59.

Ikeda K. Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. Hepatol Res. 2007 Sep;37 Suppl 2:S287-93. doi: 10.1111/j.1872-034X.2007.00199.x.




Copyright (c) 2018 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта